Log in

NASDAQ:GERN - Geron Stock Price, Forecast & News

$1.36
-0.04 (-2.86 %)
(As of 01/26/2020 12:34 PM ET)
Today's Range
$1.35
Now: $1.36
$1.40
50-Day Range
$1.29
MA: $1.41
$1.53
52-Week Range
$1.01
Now: $1.36
$2.14
Volume1.26 million shs
Average Volume1.26 million shs
Market Capitalization$271.70 million
P/E RatioN/A
Dividend YieldN/A
Beta2.28
Geron Corporation, a clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for hematologic myeloid malignancies. The company supports the clinical stage development of imetelstat, a telomerase inhibitor for the treatment of hematologic myeloid malignancies. The company was founded in 1990 and is based in Menlo Park, California.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:GERN
CUSIP37416310
Phone650-473-7700

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.07 million
Book Value$0.95 per share

Profitability

Net Income$-27,020,000.00
Net Margins-7,044.88%

Miscellaneous

Employees17
Market Cap$271.70 million
Next Earnings Date3/5/2020 (Estimated)
OptionableOptionable

Receive GERN News and Ratings via Email

Sign-up to receive the latest news and ratings for GERN and its competitors with MarketBeat's FREE daily newsletter.


Geron (NASDAQ:GERN) Frequently Asked Questions

What is Geron's stock symbol?

Geron trades on the NASDAQ under the ticker symbol "GERN."

How were Geron's earnings last quarter?

Geron Co. (NASDAQ:GERN) issued its quarterly earnings data on Wednesday, November, 6th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of ($0.14) by $0.06. The biopharmaceutical company earned $0.13 million during the quarter, compared to the consensus estimate of $0.10 million. Geron had a negative net margin of 7,044.88% and a negative return on equity of 29.22%. During the same period last year, the business posted $0.24 earnings per share. View Geron's Earnings History.

When is Geron's next earnings date?

Geron is scheduled to release their next quarterly earnings announcement on Thursday, March 5th 2020. View Earnings Estimates for Geron.

What price target have analysts set for GERN?

5 brokerages have issued 12-month price objectives for Geron's stock. Their forecasts range from $3.00 to $4.00. On average, they anticipate Geron's stock price to reach $3.80 in the next year. This suggests a possible upside of 179.4% from the stock's current price. View Analyst Price Targets for Geron.

What is the consensus analysts' recommendation for Geron?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Geron in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Geron.

Has Geron been receiving favorable news coverage?

News stories about GERN stock have trended extremely negative this week, according to InfoTrie Sentiment. The research firm identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Geron earned a media sentiment score of -4.5 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Geron.

Who are some of Geron's key competitors?

What other stocks do shareholders of Geron own?

Who are Geron's key executives?

Geron's management team includes the folowing people:
  • Dr. John A. Scarlett, CEO, Pres & Chairman (Age 68)
  • Ms. Olivia Kyusuk Bloom, Exec. VP of Fin., CFO & Treasurer (Age 50)
  • Dr. Andrew J. Grethlein, Exec. VP & COO (Age 55)
  • Mr. Stephen N. Rosenfield, Exec. VP, Chief Legal Officer & Corp. Sec. (Age 69)
  • Ms. Melissa A. Kelly Behrs, Exec. VP & Chief Bus. Officer (Age 55)

Who are Geron's major shareholders?

Geron's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Alpine Global Management LLC (0.08%) and Vision Capital Management Inc. (0.01%). Company insiders that own Geron stock include Elizabeth G O'farrell, Melissa Kelly Behrs, Robert J Spiegel and Stephen Rosenfield. View Institutional Ownership Trends for Geron.

Which major investors are buying Geron stock?

GERN stock was purchased by a variety of institutional investors in the last quarter, including Alpine Global Management LLC and Vision Capital Management Inc.. View Insider Buying and Selling for Geron.

How do I buy shares of Geron?

Shares of GERN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Geron's stock price today?

One share of GERN stock can currently be purchased for approximately $1.36.

How big of a company is Geron?

Geron has a market capitalization of $271.70 million and generates $1.07 million in revenue each year. The biopharmaceutical company earns $-27,020,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. Geron employs 17 workers across the globe.View Additional Information About Geron.

What is Geron's official website?

The official website for Geron is http://www.geron.com/.

How can I contact Geron?

Geron's mailing address is 149 COMMONWEALTH DRIVE SUITE 2070, MENLO PARK CA, 94025. The biopharmaceutical company can be reached via phone at 650-473-7700 or via email at [email protected]


MarketBeat Community Rating for Geron (NASDAQ GERN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  416 (Vote Outperform)
Underperform Votes:  348 (Vote Underperform)
Total Votes:  764
MarketBeat's community ratings are surveys of what our community members think about Geron and other stocks. Vote "Outperform" if you believe GERN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GERN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel